Leap Therapeutics, Inc. (LPTX)
Market Cap | 71.33M |
Revenue (ttm) | n/a |
Net Income (ttm) | -81.05M |
Shares Out | 25.57M |
EPS (ttm) | -5.62 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 266,714 |
Open | 2.67 |
Previous Close | 2.72 |
Day's Range | 2.65 - 2.93 |
52-Week Range | 1.24 - 10.20 |
Beta | 0.66 |
Analysts | Strong Buy |
Price Target | 14.13 (+406.45%) |
Earnings Date | Nov 13, 2023 |
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, I... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LPTX stock is "Strong Buy." The 12-month stock price forecast is $14.13, which is an increase of 406.45% from the latest price.
News

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

Leap Therapeutics Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

Leap Therapeutics to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

Leap Therapeutics Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba...

Leap Therapeutics Announces Reverse Stock Split
CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it...

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal...

Leap Therapeutics Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotec...

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights...

Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap sh...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating Leap Therapeutics, Inc. ("Leap") (NASDAQ: LPTX) regarding possible breaches of fiduciary duties and oth...

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX
NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.
NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the ...

Leap Therapeutics Acquires Flame Biosciences
Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-f...

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that D...

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

Leap Therapeutics Reports Third Quarter 2022 Financial Results
CAMBRIDGE, Mass. , Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical tri...

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that th...

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference
CAMBRIDGE, Mass. , Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that D...